Phoenix, AZ.—Beacon Biomedical Inc., a medical diagnostic development company and CLIA laboratory based in Phoenix Arizona, today announced the launch of BeScreened™-CRC, a blood-based laboratory developed test (LDT) for colorectal cancer (CRC) screening that is 95% accurate at detecting CRC in adults ages 50-75 years of age with an overall 91% sensitivity and 86% specificity for CRC stages I-IV. Preliminary study findings also indicate a greater than 60% sensitivity for detecting precancerous polyps (advanced adenomas).Continue reading
Author Archive: AZBio
Baylor Scott & White Research Institute and TGen Poised to Create Early Detection Test for Pancreatic Cancer
$5.13 million National Cancer Institute grant funds research to help identify patients before the disease causes symptoms or spreadsContinue reading
UA Project Tackles Challenge of Making Safer Melons
With funding from the U.S. Department of Agriculture, researchers will develop new disinfectants, grow new breeds of melons, and educate farmers, retailers and consumers on safe melon production practices.Continue reading
New imaging technology peers deep into the unfathomed 3D world of living single cells to advance disease diagnostics
Medical imaging technology like MRIs and CT scans have revolutionized the way patients are diagnosed with injuries and disease by enabling doctors to non-invasively look beneath the patient’s skin.
MedTech Innovator $500K Competition and Accelerator now accepting applications
The final deadline for applications is Jan. 26, 2018. Companies that apply in December will receive a priority review, so you are encouraged to apply today. Continue reading
Dignity Health and Catholic Health Initiatives to Combine to Form New Catholic Health System Focused on Creating Healthier Communities
New Organization to Preserve and Expand Access to Quality Care with Geographically Complementary Facilities Across 28 StatesContinue reading
Four Life Science Companies in the Top 10 for the Fall Arizona Innovation Challenge
Breezing, GT Medical Technologies, Life365, and Resonea are finalists for the Fall Arizona Innovation Challenge.Continue reading
FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics
Novel formulation of partial opioid offers potential benefits compared to current alternatives
FDA Provides Clearance for New Test for Valley Fever
DxNA LLC receives a de novo regulatory clearance by the FDA for the GeneSTAT.MDx™ Coccidioides Test on the GeneSTAT® Analyzer – the only FDA cleared molecular test for Valley Fever
With technology developed by TGen, the test allows for rapid definitive diagnosis of Valley FeverContinue reading